28 Aug 2025
Labcorp has helped advance over 80% of FDA-approved cell and gene therapies
BURLINGTON, N.C. (Aug. 28, 2025) – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the expansion of its cell and gene therapy (CGT) laboratory in Madison, Wisconsin. With the expansion, Labcorp has increased its capacity to deliver the most comprehensive preclinical testing capabilities to rapidly accelerate cell and gene therapy from discovery to investigational new drug application and clinical trial application.
"Labcorp is committed to helping our clients bring new treatment options to patients in need while revolutionizing the future of medicine with cell and gene therapy," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "This expansion strengthens our commitment to growing our global, comprehensive suite of CGT capabilities and our support for pharmaceutical and biotechnology companies' efforts to expedite therapeutic development."
Key features of Labcorp’s expanded facility include:
- Purpose-Built for Innovation – The new facility is designed from the ground up to support the unique complexities of CGT development. Three new surgery suites are outfitted with specialized equipment for a range of studies, including a dedicated ocular surgery suite, a stereotaxic suite and a magnetic resonance imaging (MRI)-guided surgery suite.
- Increased Capacity – With a total footprint of 26,000 square feet, the expanded CGT facility has tripled capacity. This growth enables faster study initiation, compressed timelines and accelerated progress toward key milestones.
- Broad Therapeutic Area Specialization – The preclinical research team combines doctorate-level experts with highly experienced technicians, specializing in the development of CGT targeting ocular, neurodegenerative, musculoskeletal, cardiovascular, respiratory, metabolic, oncology and autoimmune disorders.
By investing in innovative facilities and expert teams, Labcorp continues to position itself as a trusted partner in the rapidly evolving field of CGT development. This expansion is part of Labcorp's broader strategy to enhance its global capabilities for CGT and other advanced therapies.
To learn more about Labcorp’s CGT capabilities, visit https://www.labcorp.com/biopharma/central-labs/modalities/cell-gene-therapy.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.